News
INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q4 2024 Results Conference Call March 27, 2025 4:30 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Mark Lowdell - Chief Scientific Officer Christopher Barnum - Head of Neuroscience Conference Call Participants George Farmer - Scotiabank Thomas Shrader - BTIG Denis Reznik - Raymond James Elemer Piros - Rodman James Molloy - Alliance Global Partners Operator Greetings, and welcome to the INmune Bio's. 2024 Fourth Quarter and Full Year Earnings Call.
seekingalpha.com • Mar 27, 2025 20:15 Eastern
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update
BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended December 31, 2024 and provides a business update.
globenewswire.com • Mar 27, 2025 16:05 Eastern
Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West +
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering fresh ideas and fostering discussion among investors. Mitsui & Co. is given a 'buy' recommendation, driven by Warren Buffett's increased stake, stable commodity prices, and promising long-term growth from a new Australian iron ore deal. Sandisk Corporation is also seen as a 'buy' post-separation from Western Digital, with strong market performance and potential for unlocking shareholder value as an independent flash storage company.
seekingalpha.com • Mar 21, 2025 13:15 Eastern
INmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's Results
INmune Bio's CORDstrom for RDEB shows promising results, supported by FDA designations, and could lead to a 9.8x stock revaluation. XPro for Alzheimer's has significant potential, with a $24.76 billion valuation if successful, offering a 135x stock upside. CORDstrom may act as a fail-safe for INmune Bio's stock if XPro fails, ensuring a high likelihood of substantial returns.
seekingalpha.com • Mar 18, 2025 16:31 Eastern
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the “CaRe PC” trial) for men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce completion of the third and highest dose cohort of the Phase I portion of the trial allowing opening of the Phase II high dose cohort.
globenewswire.com • Feb 12, 2025 07:00 Eastern
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Boca Raton, Florida, Feb. 10, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”) , a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announced today, following a Type C meeting with the U.S. Food and Drug Administration (FDA), its intent to submit a BLA in the US and Marketing Authorization Application (MAA) in the UK and EU supported by data from the MissionEB clinical trial investigating CORDStrom as a disease-modifying therapy for treating RDEB in pediatric patients.
globenewswire.com • Feb 10, 2025 07:00 Eastern
INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025
INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to outperform current treatments and attract big pharma interest. The Phase 2 trial for XPro in Alzheimer's is fully enrolled, with topline data expected around May-June 2025, marking a pivotal moment. XPro's selective TNF inhibition has shown significant reductions in key biomarkers like ptau-217 and neurofilament light, indicating strong efficacy in neurodegenerative diseases.
seekingalpha.com • Jan 02, 2025 08:52 Eastern
INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers
INmune Bio, Inc.'s decline in 2024 is attributed to broader biotech sector issues, lack of significant clinical data, and inherent risks in Alzheimer's research. XPro, INMB's lead candidate, shows potential in early-stage trials for Alzheimer's, with crucial phase 2 data expected in Q2 2025. Financially, INMB has limited runway, with cash sufficient to fund operations only into Q3 2025, necessitating successful trial outcomes for further funding.
seekingalpha.com • Dec 30, 2024 15:20 Eastern